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ABSTRACT 
Objective: Parvovirus B19 is an important cause of chronic 
anemia in human immunodeficiency virus (HIV)-positive patients. 
Extensive seroprevalence studies for parvovirus B19 in HIV- 
positive individuals have not been carried out in the United 
States. The authors compared the seroprevalence for par- 
vovirus B19 among patients with asymptomatic HIV infection 
and healthy blood donors. 
Methods: The seroprevalence of IgG antibodies to VP-I, a par- 
vovirus 619 structural protein, was determined using an indi- 
rect enzyme immunoassay (EIA) and a Western blot assay in 
72 HIV-positive adults without prior opportunistic infection or 
acquired immunodeficiency syndrome (AIDS)-related malig- 
nancy and results were compared to those of 134 healthy 
blood donors. 
Results: There was a significantly higher seroprevalence for 
parvovirus Bi 9 in HIV-positive subjects (57/72, 79%) than in the 
controls (58/134, 43%) (P < 0.001). Analysis by indirect EIA of 
the HIV-positive subjects 1 year later showed no significant 
change in seropositivity (48/70, 69%). For HIV-positive sub- 
jects, B19 seropositivity was not significantly related to age, 
sex, or CD4 count, but the pawovirus index did correlate with 
the total IgG level at both time points (P = 0.014 at the first esti- 
mation and P = 0.045 1 year later). Western blot analysis of IgG 
antibody to the VP-l protein showed that 49 of 71 (69%) of 
the HIV-positive subjects were positive at the beginning of the 
study, and 50 of 71 (70%) were positive 1 year later. 
Conclusions: These results suggest an increased seropositiv- 
ity to parvovirus B19 among HIV-positive individuals compared 
to healthy controls. 
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Parvovirus B19 is an important human pathogen which 
causes asymptomatic childhood infection, the childhood 
exanthem erythema infectiosum (ftih disease), rheuma- 
tologic syndromes in adults, transient aplastic crisis in 
individuals with underlying hemolytic disorders, nonim- 
mune hydrops fetalis, and chronic anemia in immuno- 
compromised hosts.lm5 Parvovirus B19 shows tropism for 
erythroid progenitor cells leading to a lytic infection 
resulting in marked reticulocytopenia. Infection in human 
immunodeficiency virus (HIV)-positive individuals leads 
to decreased red blood cell production due to their inabil- 
ity to clear the virus effectively, in turn leading to 
decreased red blood cell production.’ However, in HIV- 
positive subjects, determination of the etiology of ane- 
mia is complicated by a variety of potential causes, 
including opportunistic infection, malignancy, drug toxi- 
city, inappropriately low erythropoietin, or immune medi- 
ated mechanisms. The importance of identifying 
parvovirus as an etiologic factor in HIV-positive patients 
with anemia is emphasized by the fact that effective ther- 
apy is available. Intravenous immunoglobulin has been 
successfully used to treat parvovirus-induced anemia in 
HIV-positive patients.’ 
Human parvovirus is a small DNA virus that is encap- 
sulated but lacks an envelope and has two capsid struc- 
tural proteins: the VP-2 (58 kD) major protein and the 
VP-l (83 kD) minor protein.’ Humoral immunity with 
the production of neutralizing antibody is necessary to 
effectively clear the virus.9 Antibody to the VP-l minor 
capsid protein is produced after the first week of infec- 
tion and forms the main antibody in individuals after 
recovery from acute infection.” Failure of this immune 
response results in failure to clear the virus.‘O 
Seroprevalence studies in healthy blood donors show 
varying levels of Bl9 seropositivity, depending on geo- 
graphic location. Rates of 73.7% in Rio de Janeiro, 38.4% 
in Munich, and 50% in Rochester, Minnesota, have been 
reported. 11-13 Data on the seroprevalence of antibody to 
parvovirus B19 in asymptomatic HIV-positive adults in 
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the United States is limited. Several small seroprevalence 
studies in HIV-positive individuals have shown rates rang- 
ing from 27.5% to 64%.6,7J4J5 Rates among HIV-positive 
hemophiliacs have been reported to be higher, at 91.7%.‘* 
In this study the authors determined parvovirus B19 sero- 
prevalence among HIV-positive individuals locally and 
compared this level to healthy blood donors from the 
same region. Samples were analyzed by ELISA and a con- 
firmatory Western blot was performed on the HIV-posi- 
tive individuals’ samples to assess if the results obtained 
by ELISA were specific for parvovirus, in view of the non- 
specific elevations in immunoglobulin seen early in HIV 
infection. 
SUBJECTS AND METHODS 
Subjects 
Retrospective analysis was performed on sera collected 
from 72 HIV-positive adults without prior opportunistic 
infection or AIDS-related malignancy enrolled in a sepa- 
rate study, after informed consent was obtained. The study 
was approved by the Institutional Review Boards of the 
Mayo Clinic, Park Nicollet Hospital, and the University of 
Minnesota VA Medical Center. Individuals were selected 
from HIV clinics in three urban centers in the region. All 
individuals were recently diagnosed with HIV infection 
in the absence of symptoms or anemia.The controls were 
134 geographically matched healthy blood donors from 
urban centers whose sera was collected in a separate but 
chronologically concurrent study There were slight dif- 
ferences between the control group and HIV-seroposi- 
tive group with respect to the proportion of subjects 
from each urban center. 
Serum specimens were collected from the 72 HIV- 
positive individuals after enrollment (Tl) and a repeat 
collection was obtained 1 year later (T2) in 71 of these 
individuals and analyzed by enzyme immunoassay (EIA) 
for IgG to parvovirus B19 and by Western blot for IgM 
and IgG (one subject lost to follow-up, one subject did 
not have a Western blot IgG estimation at Tl, one subject 
did not have EL4 IgG estimation at T2). CD4 counts, mea- 
sured by flow cytometry, and total IgG immunoglobulin 
levels, measured by nephelometry, also were obtained at 
the time of each sample. Each sample was analyzed by 
indirect EIA (MarDx Diagnostics, Inc., Carlsbad, CA) for 
IgG antibody to parvovirus B19 and by Western blot for 
IgM and IgG to VP-1 antigen (MarDx Diagnostics, Inc.). 
The control samples were analyzed by EL4 for IgG to par- 
vovirus B 19. 
Indirect Enzyme Immunoassay for IgG 
IgG antibody to parvovirus Bl9 was determined using 
an indirect EL4 to the VP-1 antigen in a commercially 
available test kit (MarDx Diagnostics, Inc.). Samples were 
analyzed in batch fashion using the same lot test kit.The 
performance of this kit previously has been described.l” 
The results were compared to a high positive control, 
three low positive controls, and a negative control. A par- 
vovirus index was calculated by dividing the optical den- 
sity of the sample by the mean of the three low positive 
controls.The mean high positive control index was 3.046, 
the mean negative control was 0.546, and the mean of the 
low positive controls was 1.044. Results were reported 
as positive if the parvovirus index from duplicate mea- 
surements was greater than or equal to 1.0. 
Western Blot IgM and IgG 
A Western blot for IgM and IgG was obtained on each 
sample from HIV-positive subjects (MarDx Diagnostics, 
Inc.). Western blots were read as negative, weakly posi- 
tive, or strongly positive. 
Statistics 
Statistical analysis was performed using Spearman’s rank 
correlation to compare parvovirus index versus age, CD4 
count, and immunoglobulin level. Seropositivity by indi- 
rect EIA at the two time points was compared using 
McNemar’s test, and this technique was also used to com- 
pare seropositivity at each time point by indirect EL4 
with IgG Western blot. Pearson’s &i-square test was used 
to compare differences in seropositivity by indirect EL4 
between subjects and controls. 
RESULTS 
Patient Population 
The HIV-positive subjects (n = 72) had a median age of 
38.5 years (range, 24.5-72.0 y) at the beginning of the 
study; for the controls (n = 134) the median age was 48.0 
years (range, 21 .O-79.0 y). Of the HIV-positive subjects, 
66 of 72 (92%) were male compared with 67 of 134 
(50%) for the controlsThe mode of HIV acquisition in the 
HIV-positive subjects was homosexual contact in 56 of 72 
(78%) heterosexual contact in 6 of 72 (So/,), contaminated 
hemophiliac blood products in 5 of 72 (7%) intravenous 
drug abuse in 4 of 72 (6%) and contaminated blood trans- 
fusion in 3 of 72 (4%).Two subjects had two possible 
modes of infection. Fifty-six (78%) HIV-positive individu- 
als were currently on anti-retroviral treatment: 30 (42%) 
AZT monotherapy, 4 (6%) dd1 monotherapy, 3 (4%) ddC 
monotherapy, and 19 (26%) AZT and ddC combined; and 
I6 (22%) individuals were on no therapy. The median 
CD4 count at the time of the first sample collection (Tl) 
was 280 cells/pL (range, l-704 cells/FL), and at the time 
of the sample collected 12 months later (T2) was 
200 cells/FL (range, O-765 cells/yL).The corresponding 
figures for the total IgG levels at the same two points 
were Tl, 1629 mg/dL (range, 852-3550 mg/dL) and T2, 
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Table 1. Results of Tests for Parvovirus B19 in Each Group 
Group Test Tl* T2+ 
Controls: EIA IgG 43% (58/l 34)* 
HIV-Positive: EIA IgG 79% (57/72)* 69% (48/70) 
HIV-Positive: WB IgG 69% (49/71) 70% (50/71) 
HIV-Positive: WB IgM 5.6% (4/72) 4.2% (3/71) 
Seropositivity for each test in the different groups studied. EIA = enzyme 
immunoassay; WB = Western blot; *Tl = baseline; +T2 = 1 year later; 
*P < 0.001. 
1689 mg/dL (range, 551-3759 mg/dL) (normal range for 
IgG, 500- 1200 mg/dL). 
Parvovirus IgG by Indirect Enzyme Immunoassay 
In the control population, 58 of 134 (43%) subjects were 
seropositive compared to 57 of 72 (79%) in the HIV-pos- 
itive subjects atT1 (P < 0.001) Gable l).The median par- 
vovirus index in the controls was 0.836 (range, 
0.100-5.936) compared to 1.3885 (range, 0.343-4.109) 
in the HIV-positive subjects at Tl (P = 0.008). At T2, 48 
of 70 (69%) of the HIV-positive subjects were seroposi- 
tive (see Table l), with a median parvovirus index of 
1.280 (range, 0.501-5.936), which was not significantly 
different when compared to parvovirus index at Tl The 
agreement between values at Tl and T2 was 72.9% 
(P = 0.17) (43 were positive at both times, 8 negative at 
both, 6 went from negative to positive, and 13 from pos- 
itive to negative). There was no statistical association 
between age or sex and seropositivity in either controls 
or subjects.There was no association between parvovirus 
index and CD4 count at either point in time (P = 0.868 
at Tl and P = 0.740 at T2).There was a trend toward 
seronegativity with lower total IgG immunoglobulin lev- 
els at Tl and T2, with the comparison of total IgG 
immunoglobulin level to parvovirus index at Tl, 
(P = 0.0147) and atT2, (P = 0.0454), reaching statistical 
significance. 
Western Blot Analysis 
By IgM Western blot 4 of 72 (5.6%) of HIV-positive sub- 
jects were found to be positive at Tl (see Table 1). Of 
these only one had a strong band, while the other three 
were weak. Two had positive IgG serologies, including 
the subject with a strong band, while two were IgG neg- 
ative by indirect EIA. At T2, three subjects had weak IgM 
bands by Western blot, and all three had positive bands 
at Tl (one strong, two weak).The results of IgG serolo- 
gies by indirect EL4 for all four subjects with positive 
tests for IgM atT1 were the same atT2 as they had been 
at Tl (i.e., two positive and two negative); however, one 
of those with a negative result did switch Western blot 
IgG status from negative to positive. Of 64 sera tested 
from the control population, one sample had IgM class 
antibodies to parvovirus B19. 
Western blot analysis for IgG showed 49 of 71 (69%) 
of HIV-positive subjects were positive by Western blot at 
Figure 1. Comparison of results by IgG Western blot with the par- 
vovirus index obtained by indirect EIA in the HIV-positive subjects 
shows the correlation between the tests. In particular, a number of 
specimens with low positive patvovirus index by indirect EIA were neg- 
ative by Western blot. The line shows the cutoff for parvovirus index 
of 1 .O used to determine positive results by indirect EIA. 
Tl; 25 of 49 had strong bands (see Table 1). At T2,50 of 
71 (70%) of subjects had a positive Western blot result; 
25 of 50 had strong bands. When these results were com- 
pared to the IgG results by indirect EIA they showed fair 
agreement, with 70.4% at Tl and 74.3% at T2 (Figure 1). 
DISCUSSION 
The authors found that HIV-positive individuals have a 
higher seroprevalence of IgG antibodies (79%) to par- 
vovirus Bl9 than healthy controls (43%), as determined 
by indirect EIA.Testing by IgG Western blot methods con- 
firmed a similar rate (69%) in HIV-positive individuals. 
There was no significant change in seroprevalence by 
indirect EIA or IgG Western blot after 1 year in HIV- 
seropositive individuals. In addition, parvovirus index by 
indirect EL4 was related to the total immunoglobulin level 
but not to the CD4 count. 
The rate of seropositivity in HIV-positive adults c79%) 
compares with the rate of 60% described in a mixed pop- 
ulation of 55 pediatric and adult HIV-positive cases in 
the United States and with a rate of 64% in 50 patients 
with AIDS compared with 85% in a control population 
also in the United States. 6x’ In Germany, parvovirus B19 
seroprevalence rates were 27.5% in asymptomatic HIV- 
positive nonhemophiliac subjects, 91.7% in HIV-positive 
hemophiliacs, and 34.1% for a control population.14 How- 
ever in patients with chronic anemia seropositivity was 
lower; in a study of HIV-positive patients with chronic 
anemia, only 5 of 14 patients with CD4 counts less than 
102 International Journal of Infectious Diseases / Volume 2, Number 2, October-December 1997 
200 had IgG to parvovirus and all 5 were viremic by 
Southern blot analysis of polymerase chain reaction (PCR) 
product. I5 In another study, 0 of 7 subjects with chronic 
parvovirus infection, shown by detection of viral DNA 
and capsid protein, had detectable IgG to parvovirus.7 In 
pediatric populations with AIDS, seropositivity rates tend 
to be lower: a rate of 40% was recorded in Italy and 27.5% 
in Romania.” Two studies designed to report the fre- 
quency of positive PCR tests for parvovirus DNA reported 
an incidence of IgG seropositivity of 7.6% and 81%, 
respectively.“~18 
The design of the current study improves upon these 
previous reports, because the study group represents 
adult subjects tested soon after diagnosis of their HIV 
infection and is compared to a geographically local con- 
trol group.This well-defined population is distinct from 
groups enrolled in previous studies in the United States, 
which have variously included both adult and pediatric 
populations or asymptomatic and symptomatic subjects, 
and have not always included a local control group. None 
of the previous studies compared seroprevalence results 
using different laboratory techniques or compared results 
to total IgG levels,h~7J4J5 and only one study compared 
results to the CD4 count.‘* 
The explanation of the increased seropositivity in HIV- 
positive individuals remains speculative.The attack rate of 
parvovirus B19 is high, approaching 50% in nonimmune 
adults. Spread via respiratory secretions facilitates com- 
munity spread. Pentamidine use has been suggested as a 
possible method of airborne parvovirus Bl9 transmission 
if standard precautions of ventilatory control fail to inac- 
tivate the virus. l9 However, as the current study group was 
asymptomatic and recently diagnosed with HIV infection, 
this seems an unlikely explanation. Similarly, while blood 
products, especially clotting factors, may transmit par- 
vovirus Bl9 infection, the low number of hemophiliacs or 
transfusion-related cases of HIV infection in this series, 
coupled with their asymptomatic state makes this an 
unlikely explanation. 20~21 To the authors’ knowledge there 
have been no reports of sexual transmission of parvovirus 
Bl9. However, as the HIV-positive cohort contained 48% 
homosexual men, future studies should compare the sero- 
prevalence in HIV seronegative homosexual men with that 
of HIV-seropositive homosexual men. 
The increased seropositivity noted in this group of 
HIV-positive individuals suggests unidentified methods of 
transmission may play a role, and future studies should 
investigate the potential of sexual transmission. It is not 
known if exposure to parvovirus B19 results in detectable 
antibodies for life or if parvovirus B19 is capable of estab- 
lishing latency Relapse after treatment or primary infection 
has been described.2ZJ3 It is possible that asymptomatic 
reactivation of parvovirus Bl9 associated with decreased 
cell-mediated immunity leads to an elevation of parvovirus 
B19 antibodies, an effect that may be exacerbated by the 
production of nonneutralizing antibodies. 
Although this study suggests parvovirus Bl9 infec- 
tion may occur more frequently in HIV-seropositive indi- 
viduals, the clinical relevance of this finding remains to 
be established. In contrast to findings in this study, clini- 
cal disease is rare in HIV-seropositive individuals. This 
may be because primary infection is rarely encountered, 
although findings in this study suggest prior infection is 
common and make this a less likely explanation. Alter- 
natively, reactivation of parvovirus B19 from latency may 
be a rare event or the immune response to parvovirus 
B19 may be relatively well preserved in advanced HIV 
disease. Understanding the nature of parvovirus B19 
immune determinants capable of inducing effective and 
long-lasting immunity is therefore important to vaccine 
research. 
This study has limitations. The control population 
was not identical to the subjects.There was a difference 
in age with a higher median age in the controls, which 
should have biased the study in favor of finding no dif- 
ference between groups. There also was a disparity in 
gender distribution, with the controls being evenly dis- 
tributed with respect to gender and the subjects having 
a predominance of males, consistent with the demo- 
graphics of HIV-positivity. Nevertheless these differences 
do not explain the differences in seropositivity, as the 
control group failed to show significant differences in 
seropositivity by age or sex. No evidence was found of a 
cohort effect in the controls or HIV-positive individuals. 
The makeup of the HIV-positive population differs from 
other HIV-positive populations, with a higher percentage 
of male homosexual patients and lower numbers of het- 
erosexual, intravenous drug associated, female, inner city, 
or ethnic minority cases.Therefore, findings may not be 
applicable to all HIV populations. 
Another potential limitation in this study was the 
ability to accurately diagnose parvovirus B19 seroposi- 
tivity in cases with a parvovirus index just above the 
threshold of positivity. A parvovirus index of greater than 
1 .O was used as the threshold for positivity.The kit is con- 
ventionally used, with the range 0.8-1.2 being reported 
as equivocal, and retesting being recommended. In this 
study, because there was only one sample at each time 
point, the cutoff was set at 1.0, with the understanding 
that, on an individual basis, the ability of the test kit to 
determine seropositivity might be exceeded; it was 
assumed that false positives would be balanced by false 
negatives. However, even if the results are reanalyzed to 
include equivocals, the conclusions remain unchanged. As 
Figure 1 demonstrates, samples with a parvovirus index 
of 1.0 to 2.0 frequently have a negative Western blot. In 
these cases a confirmatory positive Western blot may help 
confirm the presence of IgG antibodies.The presence of 
these samples with low positive parvovirus indices 
explains the lack of tight correlation between seroposi- 
tivity by indirect EIA at each point of time and the com- 
parison of seropositivity by indirect EIA and Western blot. 
Parvovirus B19 Antibody in HN / Dockrell et al 103 
Most of the discordant results involved specimens with 
equivocal indirect EIA values, supporting this conclusion. 
A potential concern is that the indirect EIA assay 
could just be measuring the effect of a nonspecific cross- 
reactive antibody. A strength of this study is that antibody 
to the same VP-l antigen was measured by Western blot, 
which is less likely to detect cross-reactive antibodies and 
immune complexes. Discordant results between indirect 
EIA and Western blot have been suggested to be attrib- 
utable to the production of antibody with a qualitative 
defect that does not bind to protein capsid epit0pes.l’ 
This also might explain the lack of correlation between 
antibodies detected by indirect EIA and presence of virus 
neutralization.** The production of low levels of a quali- 
tatively abnormal antibody would explain cases with a 
low positive parvovirus index and a negative Western 
blot IgG to parvovirus B19. 
The association between parvovirus index and 
immunoglobulin level was as expected. However, the asso- 
ciation of seropositivity with total IgG level did not reach 
statistical significance, suggesting that the hypergamma- 
globulinemia seen in HIV infection does not account for 
the higher seropositivity observed. A significant associa- 
tion of parvovirus seropositivity with CD4 count was not 
detected. These results suggest that, although HIV-posi- 
tive individuals with decreased CD4 counts may have less 
effective immune response to T-lymphocyte dependent 
antigens, 25 they may still retain antibodies to antigens to 
which they have previously been exposed. Lastly, the fact 
that no significant change occurred in seropositivity over 
the l-year period of observation is not surprising, as there 
would need to have been a large rate of parvovirus Bl9 
antibody decline to be detected over a l-year time period. 
CONCLUSIONS 
Asymptomatic HIV-positive adults have a higher sero- 
prevalence of parvovirus B19 IgG than do healthy blood 
donors. No evidence was found of a cross-reactive anti- 
body, and the data suggest that HrV-positive individuals 
may be at higher risk of parvovirus Bl9 infection than 
healthy controls. Seropositivity to parvovirus B19 is not sta- 
tistically correlated with total IgG levels, and previous 
studies show that patients with chronic anemia and par- 
voviremia have absent or low levels of these antibodies. 
The exact identity of these antibodies, their neutralizing 
capabilities, the mode of transmission, and the roles of 
reinfection and reactivation in parvovirus B19 infection of 
HIV-positive individuals all require further investigation. 
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